Buradasınız

Anasayfa » Content

THE LIQUISOLID TECHNIQUE: A REVIEW

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2013

Key Words:

Author Name
Abstract (2. Language): 
Poorly soluble, highly permeable active pharmaceutical ingredients (BCS Class II drugs) represent a technological challenge because their poor bioavailability is only caused by poor water solubility resulting in low drug absorption. Numerous methods have been applied to improve water solubility and drug release, respectively, among which the liquisolid technology is one of the most promising approaches. With this technique liquid formulations such as solutions or suspensions of poorly soluble drugs in a non-volatile liquid vehicle are converted into acceptably flowing and compressible powders by simple physical blending with selected excipients named the carrier and the coating material.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-liquisolid-technique-review.pdf
  • 4
464
473
  • English

REFERENCES

References: 

1. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J
Pharm.Sci.2001; 13: 123- 133.
2. Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics - A treatise. Vallabh Prakashan, Delhi, India. 2002; 19p.
3. Modi A, Tayade P. Enhancement of DissolutionProfile by Solid Dispersion (Kneading) Technique. AAPS Pharm Sci Tech 2006; 7(3): Article 68. DOI:
10.1208/pt070368.
4. Hiremath SN, Raghavendra RK, Sunil F, Danki LS, Rampure MV, Swamy PV, Bhosale UV. Dissolution enhancement of gliclazide by preparation of inclusion complexes with (3-cyclodextrin. Asian J Pharm. 2008; 2:73¬76.
5. Rasenack N, Muller BW. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res
2002; 19:1894- 1900.
6. Papadimitriou
Avgoustakis K.
SA, Bikiaris D, Microwave-induced
Available Online at www.ijprbs.com
471
Review Article CODEN: IJPRNK
Rajesh Asija, IJPRBS, 2013; Volume 2(4): 464-473
enhancement of the dissolution rate of poorly water-soluble tibolone from poly (ethylene glycol) solid dispersions. J
ApplPolymer Sci. 2008; 108: 1249-1258.
7. Smirnova I, Suttiruengwong S, Seiler M, Arlt M.n Dissolution rate enhancement by adsorption of poorly soluble drugs on hydrophilic silica aerogels. Pharm Dev Tech
2004; 9: 443-452.
8. Spireas S, Bolton M. Liquisolid Systems and Methods of Preparing Same. U.S. Patent 5,968,550, 1999.
9. Spireas S. Liquisolid Systems and Methods of Preparing Same. U.S. Patent
6,423,339 B1, 2002.
10. Khaled KA, Asiri YA, El-Sayed YM. In vivo
evaluation of liquisolid tablets in beagle dogs. Int J Pharm 2001; 222: 1-6.
11. Javadzadeh YJ, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of high dose water-insoluble drug (Carbamazepine). Int J
Pharm 2007; 34: 26-34.
12. Javadzadeh Y, Musaalrezaei L, Nokhodchi A. Liquisolid technique as a new approach to sustain propranolol hydrochloride release form tablet matrices. Int J Pharm 2008; 362:102-108.
13. Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and In vivo evaluation. Eur J Pharm Biopham 2008;
69: 993-1003.
14. Spireas S, Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pham 1998; 166:
177-188.
15. Tayel SA, Soliman II, Louis D. Improvement of dissolution preoperties of carbamazepine through application of the liquisolid technique. Eur J Pharm Biopharm
2008; 69: 342-347.
16. Ali N, Yousef J and Bacharach JN. Int J
Pharm. 2007;341:26-34.
17. Spireas SS, Jarowski CI and Roher BD. Pharm Res. 1992;9:1351-58. Stegemann S. Leveiller F. et al. When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci. 31:249-261
18. Yadav, A.V., Shete, A.S., Dabke, A.P.,
Indian J. Pharm. Educ. Res., 2010, 44(3), 227-235
19. Vidyadhara S, Babu JR, Sasidhar RLC, Ramu A, PrasadSS, Tejasree M (2011). Formulation and evaluation of glimepiride solid dispersions and their tablet formulationsfor enhanced bioavailability. International Journal of Advances in Pharmaceutical sciences. 2(1).
20. Narender T, Sukhbirlal K, Dharmesh S, Naseeb Singh T, Rahul P, Vikrant A.
21. Indian Pharmacopeia, Vol-I and II Indian Pharmacopeia Commission, Ghaziabad,Govt. of India: Ministry of Health and Family Welfare, 2007.[24] United States Pharmacopoeia Vol. I - II (USP 32Revision
Available Online at www.ijprbs.com
472
Review Article CODEN: IJPRNK
Rajesh Asija, IJPRBS, 2013; Volume 2(4): 464-473
and NF 27 edition USP NF 2009)P.Gowree
Manogar et al /J. Pharm. Sci. & Res.
Vol.3(12), 2011,1604-1611
22. Elkordy AA and Ngiik T. Effects of Liquisolid formulations on dissolution of Naproxen. Eur J Pharm Biopharm. 1-14.
23. Gubbi, S.R., Jarag, R., Research J. Pharm. And Tech., 2009, 2(2), 382-386.

Thank you for copying data from http://www.arastirmax.com